Marcos Valerio, MD
Interventional Cardiology · Miami, FLNPI 1770873317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 314 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,946, 2.6 times the $1,145 reported in 2019.
Across 314 payments — averaging $32.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Amgen$1K
- Cardiva Medical, Inc.$983
- Boston Scientific$880
- AstraZeneca$773
- Philips North America LLC$492
- plus $4K from 33 others
What the payments were for
- Food & beverage$10,133100%
- Education$460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $1,511 |
| Amgen | 49 | $1,076 |
| Cardiva Medical, Inc. | 35 | $983 |
| Boston Scientific | 20 | $880 |
| AstraZeneca | 23 | $773 |
| Philips North America LLC | 15 | $492 |
| Pfizer | 13 | $383 |
| Novartis | 17 | $345 |
| Bard Peripheral Vascular, Inc. | 8 | $344 |
| Shockwave Medical, Inc | 5 | $341 |
| Johnson & Johnson | 11 | $335 |
| Medtronic(2 entities) | 8 | $320 |
| Abiomed | 3 | $315 |
| Novo Nordisk | 16 | $259 |
| Esperion Therapeutics, Inc. | 9 | $186 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $179 |
| Omega Medical Imaging, LLC | 1 | $164 |
| E.r. Squibb & Sons, L.L.C. | 8 | $157 |
| Boehringer Ingelheim | 6 | $152 |
| Lantheus Medical Imaging, Inc. | 1 | $152 |
| Heartflow, Inc. | 2 | $118 |
| Surmodics, Inc. | 3 | $87 |
| Lilly USA, LLC | 4 | $73 |
| Inspire Medical Systems, Inc. | 1 | $60 |
| Lexicon Pharmaceuticals, Inc. | 3 | $60 |
| BD | 2 | $59 |
| Bayer | 2 | $58 |
| Impulse Dynamics (USA) Inc. | 2 | $52 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Cleerly, Inc. | 1 | $35 |
| Kestra Medical Technology Services, Inc. | 1 | $32 |
| GSK | 1 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Edwards Lifesciences | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Cardiovascular Systems Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JOT DX$315
- WATCHMAN FLX$307
- Impella$290
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$274
- Repatha$259
- FARXIGA$248
- AVEIR$163
- Definity$152
- MitraClip$140
- GALLANT$134
- Varithena Administration Pack$132
- VenaSeal$125
- XARELTO$125
- GENERAL ANGIOPLASTY$124
- BRILINTA$123
- Xience Sierra Coronary Stent$123
- Confirm Rx$123
- CARDIVA VASCADE MVP XL VVCS 10-12F$118
- IV Other$118
- ELIQUIS$109
How this compares
$10,179 in reported general payments places this provider in the 55th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 432 | $614,841 |
| EliquisApixaban | 356 | $432,598 |
| Repatha SureclickEvolocumab | 228 | $292,168 |
| FarxigaDapagliflozin Propanediol | 232 | $240,212 |
| XareltoRivaroxaban | 152 | $155,846 |
| MounjaroTirzepatide | 81 | $92,930 |
| JardianceEmpagliflozin | 56 | $68,532 |
| OzempicSemaglutide | 21 | $26,534 |
| Nebivolol Hcl | 296 | $23,412 |
| VascepaIcosapent Ethyl | 28 | $18,904 |
| RybelsusSemaglutide | 12 | $17,304 |
| BrilintaTicagrelor | 17 | $15,183 |
| Ranolazine ErRanolazine | 128 | $14,885 |
| Praluent PenAlirocumab | 19 | $12,819 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $12,011 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $345 | $614,841432 claims |
| PfizerEliquis | $383 | $432,598356 claims |
| AstraZenecaFarxiga, Brilinta | $773 | $255,395249 claims |
| Johnson & JohnsonXarelto | $335 | $155,846152 claims |
| Lilly USA, LLCMounjaro | $73 | $92,93081 claims |
| Boehringer IngelheimJardiance | $152 | $68,53256 claims |
| Novo NordiskOzempic, Rybelsus | $259 | $43,83833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Miami
- Eduardo de MarchenaMiami$498K
- Juan ZambranoMiami$173K
- Michael DyalMiami$157K
- Nish PatelMiami$149K
- Pedro Martinez-ClarkMiami$136K
- Mauricio CohenMiami$129K
- Marquand PattonMiami$112K
- Ramon QuesadaMiami$94K
- Alvaro GomezMiami$71K
- Vinod ChainaniMiami$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.